Analysts think ATAI stock price could increase by 262%
Nov 27, 2024, 12:26 PM
-26.04%
What does ATAI do
ATAI Life Sciences NV, a Berlin-based clinical-stage biopharmaceutical company, focuses on developing treatments for mental health disorders and went public on June 18, 2021. Key compounds include PCN-101 for treatment-resistant depression and DMX-1002 for opioid use disorder.
5 analysts think ATAI stock price will increase by 262.13%. The current median analyst target is $6.12 compared to a current stock price of $1.69. The lowest analysts target is $5.05 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
